ICM Pharma invests €5.25 million in Alloksys Life Sciences to support Phase 3 clinical study trials of RESCAP® drug

This is the largest investment by a Singapore pharmaceutical manufacturer for clinical trial development ICM Pharma will have exclusive manufacturing and marketing rights for RESCAP® used in cardiothoracic surgery for…

Continue Reading ICM Pharma invests €5.25 million in Alloksys Life Sciences to support Phase 3 clinical study trials of RESCAP® drug